ReviewGenes & diseases2027
Not only as a Cullin3 ligase adaptor, SPOP may also act as a molecular bridge.
Review in Genes & diseases, 2027. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Speckle-type POZ protein (SPOP), a substrate-binding adaptor of the Cullin3/RING-box1 E3 ubiquitin ligase complex, induces degradative or non-degradative ubiquitination of substrates, playing a vital role in various signaling pathways, including androgen receptor (AR)/estrogen receptor (ER)-associated signal transduction, DNA damage response, and immunity. A mountain of evidence shows that cancer-associated SPOP mutations or abnormal expression of SPOP exhibit carcinogenic or tumor-suppressive properties in human diseases, such as prostate cancer or kidney cancer. In this review, we not only summarize the structure, regulation, and pathological role of SPOP, but also highlight the SPOP-interacting proteins and their structural characteristics. Based on this, we propose a novel model in which SPOP may act as a molecular bridge, facilitating interactions between its bound proteins, which provides the possibility of forming several molecular platforms, thus gathering oncoproteins closer, resulting in the appearance of certain carcinogenic characteristics of SPOP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.